Saturday 17 October 2026
Export CBIO’s income statement to Excel — free account
Crescent Biopharma, Inc.
CBIO Healthcare Biotechnology
Crescent Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.8 million, up 108,340.0% from fiscal 2023. In the quarter to June 2026, revenue grew 1,038,900.0%, EPS grew 85.0% and free cash flow fell 7.04%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
11.84
0.64
−5.13%
Follow CBIO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | 0.00 | — |
P/S ratio |
— | — | 458.39 | — | |
P/FCF ratio |
— | — | 0.00 | — | |
P/Operating CF |
— | — | (62.48) | — | |
P/B ratio |
— | — | 3.10 | — | |
Price to Tangible BV |
— | — | 3.10 | — | |
EV/Sales |
— | — | 333.88 | — | |
EV/EBITDA |
— | — | 0.00 | — | |
EV/Operating CF |
— | — | (5.84) | — | |
EV/FCF |
— | — | (5.75) | — | |
Quick Ratio |
6.56 | 6.41 | 13.33 | 9.26 | |
Current Ratio |
6.63 | 6.56 | 13.78 | 9.66 | |
Net Debt/EBITDA |
5.15 | 2.08 | 7.67 | 6.52 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.01 | 0.00 | |
Operating CF/Net income |
0.71 | 0.29 | 0.38 | 0.78 | |
Capex/Depreciation |
(20.93) | (3.57) | (2.30) | 26.62 | |
Interest Coverage |
— | (82.28) | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 1,723.10% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 756.98% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 395.86% | 0.00% | |
Graham Net Nets |
— | — | 0.32 | — | |
Graham Number |
— | — | 0.00 | — | |
Earnings Yield |
— | — | (59.39%) | — | |
Free Cash Flow Yield |
— | — | (12.66%) | — | |
Revenue per Share |
0.00 | 0.00 | 0.03 | 0.00 | |
Operating CF per Share |
(1.06) | (2.57) | (0.29) | (0.64) | |
Capex per Share |
(0.04) | (0.02) | 0.00 | 0.06 | |
Free Cash Flow per Share |
(1.10) | (2.59) | (0.30) | (0.58) | |
Cash per Share |
8.06 | 20.47 | 6.22 | 5.62 | |
Shareholders Equity per Share |
7.05 | 19.49 | 6.05 | 5.35 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.05 | 19.49 | 6.05 | 5.35 | |
Free Cash Flow |
(18.12) | (26.93) | (9.08) | (17.71) | |
Working Capital |
114.26 | 200.58 | 181.37 | 160.47 | |
Capital Expenditures |
(0.59) | (0.19) | (0.15) | 1.76 | |
Net Current Asset Value |
112.94 | 199.37 | 180.28 | 159.50 | |
EV/EBIT |
— | — | 0.00 | — | |
Capex to Sales |
0.00 | 0.00 | 0.14 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | — | |
| Other line items | |||||
Average Receivables |
— | 9.07 | — | — | |
Average Payables |
4.71 | 8.73 | 0.65 | 4.69 | |
Average Assets |
76.98 | 137.96 | 102.56 | 170.10 | |
Average Common Equity |
62.01 | 91.77 | 91.61 | 147.25 |
Columns are period end dates